Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
: z: F/ h8 T' E6 `, CNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 " X- d0 { I Q
+ Author Affiliations
3 Q; }0 w' r8 J% q% E% D
, G* A5 W. O: v0 ]; X! G1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ) L1 ^9 o& o' C
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
: R% J) R% r1 D. G6 c2 ?; e, E3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
$ ?9 v N1 X. j2 ^ L- I6 m1 r% a4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
! A( ]6 r/ o/ Q" ^. n7 R. \1 E5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan % C6 A1 o* `$ C
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ) U5 N$ a7 I7 u; C2 }9 B
7Kinki University School of Medicine, Osaka 589-8511, Japan
+ a0 f8 F! W6 q W5 d8Izumi Municipal Hospital, Osaka 594-0071, Japan ( \. K9 }; N5 Y; O, J' G
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan ) J: E+ E2 T1 ~" V7 w0 x
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 4 P2 h- c& O+ C- e8 G- m% u B
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
$ A& I( s- _% Y6 T% O; F0 E: |- g+ }4 s( t2 `5 k/ E
|